Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.

Article Details

Citation
Copy to clipboard

Abou-Alfa GK, Lewis LD, LoRusso P, Maitland M, Chandra P, Cheeti S, Colburn D, Williams S, Simmons B, Graham RA

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.

Cancer Chemother Pharmacol. 2017 Jul;80(1):29-36. doi: 10.1007/s00280-017-3315-8. Epub 2017 May 18.

PubMed ID
28523596 [ View in PubMed
]
Abstract

PURPOSE: Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. METHODS: Patients with advanced solid malignancies and hepatic impairment were enrolled into one of four cohorts: normal [bilirubin (bili) < upper limit of normal (ULN)], mild (ULN < bili

DrugBank Data that Cites this Article

Drugs